Dipharma Francis, a global CDMO and a leading manufacturer of APIs and intermediates for generic and contract manufacturing markets, said that Kalexsyn, Inc., a Michigan corporation acquired in 2018, has been merged into its 100% owner, Dipharma Inc., a Delaware corporation and member of the Dipharma Group, effective January 1, 2022.
 
The merger represents the last step of Kalexsyn’s integration into the Dipharma Group. That process started on May 17, 2018 with the acquisition of the company, in accordance with Dipharma’s strategic decision to strengthen its position in the CDMO market and leverage its presence in the U.S.
 
“We have been working hard on combining Kalexsyn’s outstanding CRO offering with Dipharma’s strong technical competences to develop a state-of-the-art cGMP operation in Kalamazoo which now plays an essential role in Dipharma’s global business development network,” said Jorge Nogueira, chairman of Dipharma’s board and CEO of Dipharma Francis. “Now, the merger completes the formal act of that successful integration, which has enabled our company to expand the range of services we offer to our customers, both in U.S. and worldwide, from discovery research through commercialization.”